SAN DIEGO & NEW YORK--(BUSINESS WIRE)--Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Kadmon Holdings, Inc. (NYSE: KDMN) violated federal securities laws in connection with the company's "co-promotion" relationship with Valeant Pharmaceuticals, whose former employees were charged with fraud in November 2016. Kadmon, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases.
View this press release on the firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/kadmon-holdings-inc
Kadmon Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com, or via the shareholder information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.